About
Patient Care
Education
Research
Community
Add to Calendar: Outlook | Google | iCal
Topics:
Keynote Speaker:
Susan Ackerman, PhD Howard Hughes Medical Institute InvestigatorStephen W. Kuffler Chair in Biology Distinguished Professor, NeurobiologyUniversity of California, San Diego
Poster Presentation:
Posters will be presented throughout the day to encourage interactions between post-doctoral fellows, scientists and industry experts. The top three outstanding posters, selected by a panel of judges, will be awarded:
*Registration required to participate in poster presentations.
Vladimir Kefalov, Ph.D., Professor, Ophthalmology, UCI Center for Translational Vision Research; Vice Chair of Research, UCI Gavin Herbert Eye Institute; Professor, Physiology and Biophysics, University of California, Irvine
Moderator: Dorota Skowronska-Krawczyk, Ph.D, Associate Professor, Ophthalmology, UCI Center for Translational Vision Research, UCI Gavin Herbert Eye Institute; Associate Professor, Physiology & Biophysics, University of California, Irvine
Moderator: Audrone Lapinaite, Ph.D, Assistant Professor, Ophthalmology, UCI Center for Translational Vision Research, UCI Gavin Herbert Eye Institute, University of California, Irvine
Moderator: Charlotte Gore, M.D., Assistant Professor, Ophthalmology, UCI Gavin Herbert Eye Institute, University of California, Irvine
Moderator: Olivia Lee, M.D., Professor, Ophthalmology, UCI Gavin Herbert Eye Institute, University of California, Irvine
Moderator: Seanna Grob, M.D., Associate Professor, Ophthalmology, UCI, Gavin Herbert Eye Institute, University of California, Irvine
Parking is free
Abbvie
AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas – immunology, oncology, neuroscience, and eye care – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com
Dompé
Dompé is an Italian biopharmaceutical company with a 130 year legacy of medical innovation. Based in Milan with US headquarters in the San Francisco Bay Area, Dompé is committed to medical and scientific advancements that address unmet medical needs in the areas of ophthalmology, transplants, oncology, and diabetes. To learn more about Dompé, email USMedinfo@dompe.com
Genentech
Genentech, a member of the Roche Group, has more than 40 years of experience in the field of biotechnology. Genentech is researching and developing new treatments for people living with a range of eye diseases that cause significant visual impairment and blindness, including wet age-related macular degeneration (AMD), diabetic macular edema (DME), diabetic retinopathy (DR), geographic atrophy (GA), and other retinal diseases.
Glaukos
Glaukos is committed to investing in the future of ophthalmology to transform standards of care and improve patient lives. We’ve achieved many firsts in clinical studies and over the past several years, Glaukos has reinvested approximately 30% of all sales back into research and development activities – all to relentlessly advance our goal of creating and delivering transformative therapies for patients struggling with eye diseases and the skilled surgeons dedicated to their healing. Innovation is at the core of everything we do. Our mission at Glaukos is to truly transform vision by pioneering novel, dropless platforms that can meaningfully advance the standard of care and improve outcomes for patients suffering from sight-threatening chronic eye diseases. Our mantra “We’ll Go First” embodies our commitment and determination to take chances and push the limits of science and technology to disrupt and improve the legacy treatment paradigms in glaucoma, corneal disorders, and retinal diseases.
Regeneron
We are a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to numerous approved treatments and product candidates in development, almost all of which were homegrown in our laboratories. Regeneron's medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases and rare diseases.
ViaLase, Inc.
ViaLase, Inc. is a globally-minded, venture capital-backed, clinical stage medical technology company located in Aliso Viejo, CA. ViaLase is focused on disrupting the conventional glaucoma treatment paradigm with the introduction of a truly noninvasive image-guided femtosecond laser treatment that enhances glaucoma patient care. With a leadership team that has vast experience developing, designing, manufacturing, and commercializing the first femtosecond lasers for ophthalmic surgery for refractive and cataract patients, ViaLase is now bringing that expertise and innovation to glaucoma patients. ViaLase believes in collaborating closely with health care providers, payers, societies, and patients to inform our product development and commercial activities with the goal of bringing this revolutionary treatment to glaucoma patients across the globe. For more information, visit www.ViaLase.com.
Need to reach out to us for questions regarding the event? Or, are you interested in becoming a sponsor or exhibitor? Please contact us for more information.
Dana Collinson | 949-824-7243 | dana.collinson@uci.edu